

- Howlander N, Noone AM, Krapcho M, et al., eds. *SEER Cancer Statistics Review, 1975-2010*. Bethesda, MD: National Cancer Institute; 2013.
- Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. *J Clin Oncol* 2010;28:2625-2634.
- Janeway KA, Place AE, Kieran MW, et al. Future of clinical genomics in pediatric oncology. *J Clin Oncol* 2013;31:1893-1903.
- Berg SL, Grisell DL, DeLaney TF, et al. Principles of treatment of pediatric solid tumors. *Pediatr Clin North Am* 1991;38:249-267.
- Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. *J Clin Oncol* 2005;23:2004-2011.
- Blakely ML, Lobe TE, Anderson JR, et al. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma? *J Pediatr Surg* 1999;34:736-741.
- Simon T, Haberle B, Hero B, et al. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. *J Clin Oncol* 2013;31:752-758.
- Raney B, Stoner J, Anderson J, et al. Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group. *J Pediatr Surg* 2010;45:2160-2168.
- Flamant F, Rodary C, Rey A, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. *Eur J Cancer* 1998;34:1050-1062.
- Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. *J Clin Oncol* 1995;13:610-630.
- Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. *Nat Rev Cancer* 2003;3:203-216.
- Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. *Lancet* 2007;369:2106-2120.
- Maris JM. Recent advances in neuroblastoma. *N Engl J Med* 2010;362:2202-2211.
- Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. *Hematol Oncol Clin North Am* 2010;24:65-86.
- Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. *Curr Opin Pediatr* 2005;17:7-13.
- Goodman MT, Gurney JG, Smith MA, et al. Sympathetic nervous system tumors. In: Ries LAG, Smith MA, Gurney JG, et al., eds. *Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995*. National Cancer Institute, SEER Program. Bethesda, MD: National Cancer Institute; 1999: 65-72.
- London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. *J Clin Oncol* 2005;23:6459-6465.
- Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. *Cancer* 1986;57:1887-1893.
- Maris JM, Kyemba SM, Rebbeck TR, et al. Molecular genetic analysis of familial neuroblastoma. *Eur J Cancer* 1997;33:1923-1928.
- Maris JM, Weiss MJ, Mosse Y, et al. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. *Cancer Res* 2002;62:6651-6658.
- Tonini GP, Longo L, Coco S, et al. Familial neuroblastoma: a complex heritable disease. *Cancer Lett* 2003;197:41-45.
- Shojaei-Brosseau T, Chompret A, Abel A, et al. Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France. *Pediatr Blood Cancer* 2004;42:99-105.
- Longo L, Panza E, Schena F, et al. Genetic predisposition to familial neuroblastoma: identification of two novel genomic regions at 2p and 12p. *Human Hered* 2007;63:205-211.
- Knudson AG Jr, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. *Am J Hum Genet* 1972;24:514-532.
- Mosse YP, Laundslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. *Nature* 2008;455:930-935.
- Lemire EG, Chodirker BN, Williams GJ, et al. Familial neuroblastoma: report of a kindred with later age at diagnosis. *J Pediatr Hematol Oncol* 1998;20:489-493.
- Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. *Nature* 2008;455:971-974.
- George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. *Nature* 2008;455:975-978.
- Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. *Nature* 2008;455:967-970.
- Ogawa S, Takita J, Sanada M, et al. Oncogenic mutations of ALK in neuroblastoma. *Cancer Sci* 2011;102:302-308.
- Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. *Am J Hum Genet* 2004;74:761-764.
- Mosse YP, Laundslager M, Khazi D, et al. Germline PHOX2B mutation in hereditary neuroblastoma. *Am J Hum Genet* 2004;75:727-730.
- Raabe EH, Laundslager M, Winter C, et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. *Oncogene* 2008;27:469-476.
- Nemecek ER, Sawin RW, Park J. Treatment of neuroblastoma in patients with neurocristopathy syndromes. *J Pediatr Hematol Oncol* 2003;25:159-162.
- Maris JM, Chatten J, Meadows AT, et al. Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease. *Med Pediatr Oncol* 1997;28:1-5.
- Stovroff M, Dykes F, Teague WC. The complete spectrum of neurocristopathy in an infant with congenital hypoventilation, Hirschsprung's disease, and neuroblastoma. *J Pediatr Surg* 1995;30:1218-1221.
- Kushner BH, Hajdu SI, Helson L. Synchronous neuroblastoma and von Recklinghausen's disease: a review of the literature. *J Clin Oncol* 1985;3:117-120.
- The I, Murthy AE, Hannigan GE, et al. Neurofibromatosis type 1 gene mutations in neuroblastoma. *Nat Genet* 1993;3:62-66.
- Blatt J, Olshan AF, Lee PA, Ross JL. Neuroblastoma and related tumors in Turner's syndrome. *J Pediatr* 1997;131:666-670.
- DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. *J Pediatr* 1998;132:398-400.
- Anderson DJ, Carnahan JF, Michelsohn A, et al. Antibody markers identify a common progenitor to sympathetic neurons and chromaffin cells in vivo and reveal the timing of commitment to neuronal differentiation in the sympathoadrenal lineage. *J Neurosci* 1991;11:3507-3519.
- Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. *J Natl Cancer Inst* 1984;73:405-416.
- Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. *Cancer* 1999;86:349-363.
- Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). *Cancer* 1999;86:364-372.
- Peuchmaur M, d'Amore ES, Joshi VV, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. *Cancer* 2003;98:2274-2281.
- Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. *Cancer* 2001;92:2451-2461.
- Schwab M, Alitalo K, Klemmner KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. *Nature* 1983;305:245-248.
- Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. *Science* 1984;224:1121-1124.
- Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. *N Engl J Med* 1985;313:1111-1116.
- Maris JM, Matthay KK. Molecular biology of neuroblastoma. *J Clin Oncol* 1999;17:2264-2279.
- Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. *J Clin Oncol* 2009;27:289-297.
- Kaneko Y, Kanda N, Maseki N, et al. Different karyotypic patterns in early and advanced stage neuroblastomas. *Cancer Res* 1987;47:311-318.
- Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. *N Engl J Med* 1984;311:231-235.
- Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. *J Clin Oncol* 1991;9:581-591.
- Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. *N Engl J Med* 2005;353:2243-2253.
- Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. *N Engl J Med* 1999;340:1954-1961.
- Brodeur GM, et al. Trk receptor expression and inhibition in neuroblastomas. *Clin Cancer Res* 2009;15:3244-3250.
- Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. *Cancer Res* 2002;62:6462-6466.
- Cheung NK, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. *JAMA* 2012;307:1062-1071.
- Vandepoel K, Van Roy N, Staes K, et al. A novel gene family NBPF: intricate structure generated by gene duplications during primate evolution. *Mol Biol Evol* 2005;22:2265-2274.
- Diskin SJ, Hou C, Glessner JT, et al. Copy number variation at 1q21.1 associated with neuroblastoma. *Nature* 2009;459:987-991.

62. Janoueix-Lerosey I, Schliermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. *J Clin Oncol* 2009;27:1026–1033.
63. De Preter K, Vermeulen J, Brors B, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. *Clin Cancer Res* 2010;16:532–1541.
64. Schliermacher G, Michon J, Huon I, et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. *Br J Cancer* 2007;97:238–246.
65. Mosse YP, Diskin SJ, Wasserman N, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. *Genes Chromosomes Cancer* 2007;46:936–949.
66. Oberthuer A, Berthold F, Wamat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. *J Clin Oncol* 2006;24:5070–5078.
67. Oberthuer A, Wamat P, Kahlert Y, et al. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. *Cancer Lett* 2007;250:250–267.
68. Tomioka N, Oba S, Ohira M, et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. *Oncogene* 2008;27:441–449.
69. Maris JM, Mosse YP, Bradfield JP, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. *N Engl J Med* 2008;358:2585–2593.
70. Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. *Nat Genet* 2009;41:718–723.
71. Wang K, Diskin SJ, Zhang H, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. *Nature* 2011;469:216–220.
72. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. *J Pediatr Hematol Oncol* 1999;21:181–189.
73. Timmerman R. Images in clinical medicine. Raccoon eyes and neuroblastoma. *N Engl J Med* 2003;349:e4.
74. Simon T, Niemann CA, Hero B, et al. Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. *Dev Med Child Neurol* 2012;54:347–352.
75. Belgaumi AF, Kauffman WM, Jenkins JJ, et al. Blindness in children with neuroblastoma. *Cancer* 1997;80:1997–2004.
76. Lucky AW, McGuire J, Komp DM. Infantile neuroblastoma presenting with cutaneous blanching nodules. *J Am Acad Dermatol* 1982;6:389–391.
77. LaBrosse EH, Comoy E, Bohuon C, et al. Catecholamine metabolism in neuroblastoma. *J Natl Cancer Inst* 1976;57:633–638.
78. Monsaingeon M, Perel Y, Simonnet G, et al. Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma. *Eur J Pediatr* 2003;162:397–402.
79. Strenger V, Perel Y, Simonnet G, et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. *Pediatr Blood Cancer* 2007;48:504–509.
80. O'Meara A, Tormey W, FitzGerald RJ, et al. Interpretation of random urinary catecholamines and their metabolites in neuroblastoma. *Acta Paediatr* 1994;83:88–92.
81. Bourdeaut F, de Carli E, Timsit S, et al. VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the Societe Francaise des Cancers de l'Enfant (SFCE). *Pediatr Blood Cancer* 2009;52:585–590.
82. Wilson J. Neuroimmunology of dancing eye syndrome in children. *Dev Med Child Neurol* 2006;48:693–696.
83. Gorman MP. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. *Curr Opin Pediatr* 2010;22:745–750.
84. Brunklaus A, Pohl K, Zuberi SM, et al. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. *Pediatrics* 2011;128:e388–e394.
85. Raffaghello L, Conte M, De Grandis E, et al. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma. *Eur J Paediatr Neurol* 2009;13:219–223.
86. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies—a report from the Children's Cancer Group Study. *Med Pediatr Oncol* 2001;36:612–622.
87. Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma: a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. *Cancer Lett* 2005;228:275–282.
88. Russo C, Cohn SL, Petruzzi MJ, et al. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. *Med Pediatr Oncol* 1997;28:284–288.
89. Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. *J Pediatr* 2001;139:552–559.
90. De Bernardi B, Balwierz W, Bejent J, et al. Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. *Cancer Lett* 2005;228:283–299.
91. De Bernardi B, Pianca C, Pistamiglio P, et al. Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. *J Clin Oncol* 2001;19:183–190.
92. Poretti A, Grotzer MA. Neuroblastoma with spinal cord compression: is there an emergency treatment of choice? *Dev Med Child Neurol* 2012;54:297–298.
93. Hoover M, Bowman LC, Crawford SE, et al. Long-term outcome of patients with intraspinal neuroblastoma. *Med Pediatr Oncol* 1999;32:353–359.
94. Katzenstein HM, Kent PM, London WB, Cohn SL. Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. *J Clin Oncol* 2001;19:1047–1055.
95. Aydin GB, Kutluk MT, Buyukpamukcu M, et al. Neurological complications of neuroblastic tumors: experience of a single center. *Childs Nerv Syst* 2010;26:359–365.
96. Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by (123I)-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. *Br J Cancer* 2010;102:1319–1326.
97. Mueller WP, Coppenrath E, Pfluger T. Nuclear medicine and multimodality imaging of pediatric neuroblastoma. *Pediatr Radiol* 2013;43:418–427.
98. Sharp SE, Shulkin BL, Gelfand MJ, et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. *J Nucl Med* 2009;50:1237–1243.
99. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. *J Clin Oncol* 1993;11:1466–1477.
100. Piccardo A, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. *European journal of nuclear medicine and molecular imaging* 2012;39:57–71.
101. Brodeur GM. Are bone marrow aspirates or biopsies the preferred method to detect metastatic neuroblastoma to bone marrow? *J Pediatr Hematol Oncol* 1998;20:297–298.
102. Gould VE, Wiedenmann B, Lee I, et al. Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. *Am J Pathol* 1987;126:243–257.
103. Park SJ, Park CJ, Kim S, et al. Detection of bone marrow metastases of neuroblastoma with immunohistochemical staining of CD56, chromogranin A, and synaptophysin. *Appl Immunohistochem Mol Morphol* 2010;18:348–352.
104. Treuner J, Schilling FH. Neuroblastoma mass screening: the arguments for and against. *Eur J Cancer* 1995;31A:565–568.
105. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. *N Engl J Med* 2002;346:1047–1053.
106. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. *N Engl J Med* 2002;346:1041–1046.
107. Morris JK. Screening for neuroblastoma in children. *J Med Screen* 2002;9:56.
108. Schilling FH, Spix C, Berthold F, et al. Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. *Cancer Lett* 2003;197:19–28.
109. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. *J Clin Oncol* 1988;6:1874–1881.
110. Kushner BH, Kramer K, LaQuaglia MP, et al. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. *Med Pediatr Oncol* 2003;41:508–515.
111. Franks LM, Bollen A, Seeger RC, et al. Neuroblastoma in adults and adolescents: an indolent course with poor survival. *Cancer* 1997;79:2028–2035.
112. Conte M, Parodi S, De Bernardi B, et al. Neuroblastoma in adolescents: the Italian experience. *Cancer* 2006;106:1409–1417.
113. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. *J Clin Oncol* 2009;27:298–303.
114. Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. *J Pediatr Hematol Oncol* 2000;22:197–205.
115. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. *J Clin Oncol* 2000;18:18–26.
116. Castleberry RP, Shuster JJ, Altshuler G, et al. Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited post-operative chemotherapy: a Pediatric Oncology Group study. *J Clin Oncol* 1992;10:1299–1304.
117. Nuchtern JC, London WB, Barnewell CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. *Ann Surg* 2012;256:573–580.
118. Matthay KK. Stage 4S neuroblastoma: what makes it special? *J Clin Oncol* 1998;16:2003–2006.
119. Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience—a pediatric oncology group study. *J Clin Oncol* 1998;16:2007–2017.
120. Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. *J Clin Oncol* 2000;18:477–486.
121. Taggart DR, London WB, Schmidt ML, et al. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. *J Clin Oncol* 2011;29:4358–4364.

122. Baker DL, Schmidt ML, Cohn SI, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. *N Engl J Med* 2010;363:1313–1323.
123. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. *J Clin Oncol* 1998;16:1256–1264.
124. Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. *J Clin Oncol* 2005;23:8819–8827.
125. Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. *J Clin Oncol* 2011;29:449–455.
126. London WB, Castel V, Monclair T, et al. Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. *J Clin Oncol* 2011;29:3286–3292.
127. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. *J Clin Oncol* 1994;12:2607–2613.
128. Castleberry RP, Cantor AB, Green AA, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. *J Clin Oncol* 1994;12:1616–1620.
129. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. *N Engl J Med* 1999;341:1165–1173.
130. Coze C, Hartmann O, Michon J, et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. *J Clin Oncol* 1997;15:3433–3440.
131. Tweddle DA, Pinkerton CR, Lewis IJ, et al. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. *Med Pediatr Oncol* 2001;36:239–242.
132. Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. *J Clin Oncol* 2005;23:4039–4047.
133. Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group Study. *J Clin Oncol* 2011;29:4351–4357.
134. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. *J Clin Oncol* 2003;21:1592–1601.
135. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. *J Clin Oncol* 1991;9:1050–1058.
136. Pinkerton CR, Blane Vincent MP, Bergeron C, et al. Induction chemotherapy in metastatic neuroblastoma—does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). *Eur J Cancer* 2000;36:1808–1815.
137. Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. *Lancet Oncol* 2008;9:247–256.
138. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. *J Clin Oncol* 2003;21:2486–2491.
139. Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. *J Nucl Med* 2013;54:541–548.
140. Schmidt M, Simon T, Hero B, et al. The prognostic impact of functional imaging with (123I)mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. *Eur J Cancer* 2008;44:1552–1558.
141. Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. *J Clin Oncol* 2000;18:4067–4076.
142. Beiske K, Burchill SA, Cheung IY, et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. *Br J Cancer* 2009;100:1627–1637.
143. La Quaglia MP, Kushner BH, Heller G, et al. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. *J Pediatr Surg* 1994;29:1162–1165.
144. Haase GM, O'Leary MC, Ramsay NK, et al. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. *J Pediatr Surg* 1991;26:1119–1123.
145. La Quaglia MP, Kushner BH, Su W, et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. *J Pediatr Surg* 2004;39:412–417.
146. Adkins ES, Sawin R, Gerbing RB, et al. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. *J Pediatr Surg* 2004;39:931–936.
147. Koh CC, Sheu JC, Liang DC, et al. Complete surgical resection plus chemotherapy prolongs survival in children with stage 4 neuroblastoma. *Pediatr Surg Int* 2005;21:69–72.
148. Tsuchida Y, Yokoyama J, Kaneko M, et al. Therapeutic significance of surgery in advanced neuroblastoma: a report from the study group of Japan. *J Pediatr Surg* 1992;27:616–622.
149. Shorter NA, Davidoff AM, Evans AE, et al. The role of surgery in the management of stage IV neuroblastoma: a single institution study. *Med Pediatr Oncol* 1995;24:287–291.
150. Medary I, Aronson D, Cheung NK, et al. Kinetics of primary tumor regression with chemotherapy: implications for the timing of surgery. *Ann Surg Oncol* 1996;3:521–525.
151. McGregor LM, Rao BN, Davidoff AM, et al. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience. *Cancer* 2005;104:2837–2846.
152. Kushner BH, Kramer K, LaQuaglia MP, et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. *J Clin Oncol* 2004;22:4888–4892.
153. Cecchetto G, Mosseri V, De Bernardi B, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. *J Clin Oncol* 2005;23:8483–8489.
154. Bowman LC, Hancock ML, Santana VM, et al. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St. Jude Children's Research Hospital experience, 1962 to 1988. *J Clin Oncol* 1991;9:1599–1608.
155. Matthay KK, O'Leary MC, Ramsay NK, et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. *Eur J Cancer* 1995;31A:572–575.
156. Pritchard J. "Megatherapy" for advanced neuroblastoma—rationale and role. *Eur J Cancer* 1995;31A:134–136.
157. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. *J Clin Oncol* 1996;14:2417–2426.
158. Yalcin B, Kremer LC, Caron HN, et al. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. *Cochrane Database Syst Rev* 2013;8:CD006301.
159. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. *Lancet Oncol* 2005;6:649–658.
160. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. *J Clin Oncol* 2009;27:1007–1013.
161. Ladenstein R, Potschger U, Hartman O, et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. *Bone Marrow Transplant* 2008;41:S118–S127.
162. Molina B, Alonso L, Gonzalez-Vicent M, et al. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients. *Pediatr Hematol Oncol* 2011;28:115–123.
163. Valteau-Couanet D, Benhamou E, Vassal G, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. *Bone Marrow Transplant* 2000;25:937–942.
164. Ladenstein R, Potschger U, Luksch R, et al. Final results from the HR-NBL1/SIOPEN trial favour busulphan-melphalan as superior myeloablative therapy (MAT) for high risk neuroblastoma. *J Clin Oncol* 2011;29:2.
165. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. *Blood* 1994;84:380–383.
166. Kreissman SC, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. *Lancet Oncol* 2013;14:999–1008.
167. Philip T, Ladenstein R, Zucker JM, et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. *Br J Cancer* 1993;67:119–127.
168. Grupp SA, Stern JW, Bunin N, et al. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. *Med Pediatr Oncol* 2000;35:696–700.
169. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. *J Clin Oncol* 2000;18:2567–2575.
170. Moreau LA, Mcgrady P, London WB, et al. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. *Clin Cancer Res* 2006;12:5693–5697.
171. Granger M, Grupp SA, Kletzel M, et al. Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in



- a cooperative group setting: a Pediatric Oncology Group study: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2012;59:902–907.
172. Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. *Bone Marrow Transplant* 2013;48:947–952.
  173. Flandin I, Hartmann O, Michon J, et al. Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology. *Int J Radiat Oncol Biol Phys* 2006;64:1424–1431.
  174. Bradfield SM, Douglas JG, Hawkins DS, et al. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. *Cancer* 2004;100:1268–1275.
  175. Kushner BH, O'Reilly RJ, Mandell LR, et al. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. *J Clin Oncol* 1991;9:274–279.
  176. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. *J Clin Oncol* 2001;19:2821–2828.
  177. Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. *Int J Radiat Oncol Biol Phys* 2003;56:28–39.
  178. More SS, Renuka PS, Pruthi K, et al. Isolation, purification, and characterization of fungal laccase from *Pleurotus sp.* *Enzyme Res* 2011;2011:248735.
  179. Paulino AC. Palliative radiotherapy in children with neuroblastoma. *Pediatr Hematol Oncol* 2003;20:111–117.
  180. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. *N Engl J Med* 2010;363:1324–1334.
  181. Termuhlen AM, Tersak JM, Liu Q, et al. Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study. *Pediatr Blood Cancer* 2011;57:1210–1216.
  182. Ries LAG, Smith MA, Gurney JG, et al., eds. *Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995*. Bethesda, MD: National Cancer Institute SEER Program; 1999.
  183. Grovas A, Fremgen A, Rauck A, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. *Cancer* 1997;80:2321–2332.
  184. Breslow N, Beckwith JB, Ciol M, et al. Age distribution of Wilms' tumor: report from the National Wilms' Tumor Study. *Cancer Res* 1988;48:1653–1657.
  185. Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. *Nat Rev Cancer* 2005;5:699–712.
  186. Dome JS, Coppes MJ. Recent advances in Wilms tumor genetics. *Curr Opin Pediatr* 2002;14:5–11.
  187. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. *Hum Mol Genet* 2006;15:R196–R201.
  188. Porteus MH, Narkool P, Neuberg D, et al. Characteristics and outcome of children with Beckwith-Wiedemann syndrome and Wilms' tumor: a report from the National Wilms Tumor Study Group. *J Clin Oncol* 2000;18:2026–2031.
  189. Green DM, Breslow NE, Beckwith JB, et al. Screening of children with hemihypertrophy, aniridia, and Beckwith-Wiedemann syndrome in patients with Wilms tumor: a report from the National Wilms Tumor Study. *Med Pediatr Oncol* 1993;21:188–192.
  190. Scott RH, Walker L, Olsen OE, et al. Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. *Arch Dis Child* 2006;91:995–999.
  191. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. *Cancer* 1978;41:1937–1948.
  192. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor—new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. *Am J Surg Pathol* 1996;20:909–920.
  193. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. *J Clin Oncol* 2006;24:2352–2358.
  194. Spreafico F, Collini P, Terenziani M, et al. Renal cell carcinoma in children and adolescents. *Expert Rev Anticancer Ther* 2010;10:1967–1978.
  195. Schmidt D, Harms D, Evers KG, et al. Bone metastasizing renal tumor (clear cell sarcoma) of childhood with epithelioid elements. *Cancer* 1985;56:609–613.
  196. Wick MR, Ritter JH, Dehner LP. Malignant rhabdoid tumors: a clinicopathologic review and conceptual discussion. *Semin Diagn Pathol* 1995;12:233–248.
  197. Roberts CW, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. *Cancer Biol Ther* 2009;8:412–416.
  198. Biegel JA, Tan L, Zhang F, et al. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. *Clin Cancer Res* 2002;8:3461–3467.
  199. Howell CG, Othersen GB, Kiviat NE, et al. Therapy and outcome in 51 children with mesoblastic nephroma: a report of the National Wilms' Tumor Study. *J Pediatr Surg* 1982;17:826–831.
  200. Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. *Cancer Res* 1998;58:5046–5048.
  201. Coppes MJ, Arnold M, Beckwith JB, et al. Factors affecting the risk of contralateral Wilms tumor development: a report from the National Wilms' Tumor Study Group. *Cancer* 1999;85:1616–1625.
  202. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. *Pediatr Pathol* 1990;10:1–36.
  203. Hennigar RA, O'Shea PA, Grattan-Smith JD. Clinicopathologic features of nephrogenic rests and nephroblastomatosis. *Adv Anat Pathol* 2001;8:276–289.
  204. Bergeron C, Iliescu C, Thiess P, et al. Does nephroblastomatosis influence the natural history and relapse rate in Wilms' tumour? A single centre experience over 11 years. *Eur J Cancer* 2001;37:385–391.
  205. Hing S, Lu YJ, Summersgill B, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. *Am J Pathol* 2001;158:393–398.
  206. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. *J Clin Oncol* 2005;23:7312–7321.
  207. Perlman EJ, Grundy PE, Anderson JR, et al. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: a children's oncology group study. *J Clin Oncol* 2011;29:698–703.
  208. Green DM, Jaffe N. Wilms' tumor—model of a curable pediatric malignant solid tumor. *Cancer Treat Rev* 1978;5:143–172.
  209. Madre C, Orbach D, Baudouin V, et al. Hypertension in childhood cancer: a frequent complication of certain tumor sites. *J Pediatr Hematol Oncol* 2006;28:659–664.
  210. Auldust AW. Wilms' tumor presenting as a varicocele. *J Pediatr Surg* 1976;11:471–472.
  211. Gyls-Morin V, Hoffer FA, Kozakewich H, et al. Wilms tumor and nephroblastomatosis: imaging characteristics at gadolinium-enhanced MR imaging. *Radiology* 1993;188:517–521.
  212. Ehrlich PF, Hamilton TE, Grundy P, et al. The value of surgery in directing therapy for patients with Wilms' tumor with pulmonary disease. A report from the National Wilms' Tumor Study Group (National Wilms' Tumor Study 5). *J Pediatr Surg* 2006;41:162–167.
  213. Metzger ML, Dome JS. Current therapy for Wilms' tumor. *Oncologist* 2005;10:815–826.
  214. Green DM. Controversies in the management of Wilms tumor - immediate nephrectomy or delayed nephrectomy? *Eur J Cancer* 2007;43:2453–2456.
  215. Petrucci MJ, Green DM. Wilms' tumor. *Pediatr Clin North Am* 1997;44:939–952.
  216. Shamberger RC, Guthrie KA, Ritchey ML, et al. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. *Ann Surg* 1999;229:292–297.
  217. Ritchey ML, Green DM, Breslow NB, et al. Re: Is contralateral exploration of the kidney necessary in patients with Wilms tumor? *J Urol* 1997;158:186.
  218. Ritchey ML, Shamberger RC, Hamilton T, et al. Fate of bilateral renal lesions missed on preoperative imaging: a report from the National Wilms' Tumor Study Group. *J Urol* 2005;174:1519–1521.
  219. Green DM, Breslow NE, Beckwith JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. *J Clin Oncol* 2001;19:3719–3724.
  220. Shamberger RC, Anderson JR, Breslow NE, et al. Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. *Ann Surg* 2010;251:555–558.
  221. Hamilton TE, Ritchey ML, Haase GM, et al. The management of synchronous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group. *Ann Surg* 2011;253:1004–1010.
  222. Breslow NE, Takashima JR, Ritchey ML, et al. Renal failure in the Denys-Drash and Wilms' tumor-aniridia syndromes. *Cancer Res* 2000;60:4030–4032.
  223. Breslow NE, et al. End stage renal disease in patients with Wilms tumor: results from the National Wilms' Tumor Study Group and the United States Renal Data System. *J Urol* 2005;174:1972–1975.
  224. Ritchey ML, Kelalis PP, Haase GM, et al. Preoperative therapy for intracaval and atrial extension of Wilms tumor. *Cancer* 1993;71:4104–4110.
  225. Shamberger RC, Ritchey ML, Haase GM, et al. Intravascular extension of Wilms tumor. *Ann Surg* 2001;234:116–121.
  226. Ritchey ML. The role of preoperative chemotherapy for Wilms' tumor: the NWTSG perspective. National Wilms' Tumor Study Group. *Semin Urol Oncol* 1999;17:21–27.
  227. Green DM, Breslow NE, Li Y, et al. The role of surgical excision in the management of relapsed Wilms' tumor patients with pulmonary metastases: a report from the National Wilms' Tumor Study. *J Pediatr Surg* 1991;26:728–733.
  228. Tournade MF, Com-Nougue C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. *J Clin Oncol* 2001;19:488–500.
  229. de Kraker J, Graf N, van Tinteren H, et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. *Lancet* 2004;364:1229–1235.
  230. Graf N, van Tinteren H, Bergeron C, et al. Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01. *Eur J Cancer* 2012;48:3240–3248.

231. Pritchard-Jones K, Moroz V, Vujanec G, et al. Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial. *Ann Oncol* 2012;23:2457–2463.
232. Breslow NE, Ou SS, Beckwith JB, et al. Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies. *Cancer* 2004;101:1072–1080.
233. Dome JS, Fernandez CV, Mullen EA, et al. Children's Oncology Group's 2013 blueprint for research: renal tumors. *Pediatr Blood Cancer* 2013;60:994–1000.
234. D'Angio CJ, Breslow N, Beckwith JB, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. *Cancer* 1989;64:349–360.
235. Green DM. The treatment of stages I-IV favorable histology Wilms' tumor. *J Clin Oncol* 2004;22:1366–1372.
236. Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. *J Clin Oncol* 1998;16:3744–3751.
237. Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. *Pediatr Blood Cancer* 2007;48:493–499.
238. Malogolowkin M, Spreafico F, Dome JS, et al. Incidence and outcomes of patients with late recurrence of Wilms' tumor. *Pediatr Blood Cancer* 2013;60:1612–1615.
239. Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. *Pediatr Blood Cancer* 2008;50:236–241.
240. Dome JS, Liu T, Krasin M, et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. *J Pediatr Hematol Oncol* 2002;24:192–198.
241. Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. *Ann Oncol* 2002;13:460–469.
242. Ha TC, Spreafico F, Graf N, et al. An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour. *Eur J Cancer* 2013;49:194–210.
243. Garaventa A, Hartmann O, Bernard JL, et al. Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. *Med Pediatr Oncol* 1994;22:11–14.
244. Metzger ML, Stewart CF, Freeman BB 3rd, et al. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. *J Clin Oncol* 2007;25:3130–3136.
245. Venkatramani R, Malogolowkin MH, Mascarenhas L. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. *Pediatr Blood Cancer* 2014;61:756–759.
246. Thomas PR, Tefft M, Compaan PJ, et al. Results of two radiation therapy randomizations in the third National Wilms' Tumor Study. *Cancer* 1991;68:1703–1707.
247. Kalapurakal JA, Li SM, Breslow NE, et al. Influence of radiation therapy delay on abdominal tumor recurrence in patients with favorable histology Wilms' tumor treated on NWT3-3 and NWT3-4: a report from the National Wilms' Tumor Study Group. *Int J Radiat Oncol Biol Phys* 2003;57:495–499.
248. Grundy PE, Green DM, Dirks AC, et al. Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2012;59:631–635.
249. Verschuur A, Van Tinteren H, Graf N, et al. Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy. *J Clin Oncol* 2012;30:3533–3539.
250. Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. *Br J Ophthalmol* 2009;93:1129–1131.
251. Friend SH, Bernards R, Rogeij S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 1986;323:643–646.
252. Matsunaga E. Hereditary retinoblastoma: penetrance, expressivity and age of onset. *Hum Genet* 1976;33:1–15.
253. Mitter D, Ullmann R, Muradyan A, et al. Genotype-phenotype correlations in patients with retinoblastoma and interstitial 13q deletions. *Eur J Hum Genet* 2011;19:947–958.
254. Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. *Lancet Oncol* 2013;14:327–334.
255. Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. *Nature* 2012;481:329–334.
256. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. *JAMA* 1997;278:1262–1267.
257. Moll AC, Imhof SM, Bouter LM, et al. Second primary tumors in patients with retinoblastoma. A review of the literature. *Ophthalmic Genet* 1997;18:27–34.
258. Kleinerman RA, Yu CL, Little MP, et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. *J Clin Oncol* 2012;30:950–957.
259. Yu CL, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. *J Natl Cancer Inst* 2009;101:581–591.
260. Sang DN, Albert DM. Retinoblastoma: clinical and histopathologic features. *Hum Pathol* 1982;13:133–147.
261. Howard GM, Ellsworth RM. Differential diagnosis of retinoblastoma. A statistical survey of 500 children. II. Factors relating to the diagnosis of retinoblastoma. *Am J Ophthalmol* 1965;60:618–621.
262. Ellsworth RM. The practical management of retinoblastoma. *Trans Am Ophthalmol Soc* 1969;67:462–534.
263. Shields JA, Leonard BC, Michelson JB, et al. B-scan ultrasonography in the diagnosis of atypical retinoblastomas. *Can J Ophthalmol* 1976;11:42–51.
264. Shields CL, Shields JA. Diagnosis and management of retinoblastoma. *Cancer Control* 2004;11:317–327.
265. Wilson MW, Rodriguez-Galindo C, Billups C, et al. Lack of correlation between the histologic and magnetic resonance imaging results of optic nerve involvement in eyes primarily enucleated for retinoblastoma. *Ophthalmology* 2009;116:1558–1563.
266. Freeman CR, Esseltine DL, Whitehead VM, et al. Retinoblastoma: the case for radiotherapy and for adjuvant chemotherapy. *Cancer* 1980;46:1913–1918.
267. MacKay CJ, Abramson DH, Ellsworth RM. Metastatic patterns of retinoblastoma. *Arch Ophthalmol* 1984;102:391–396.
268. Pratt CB, Meyer D, Chenaille P, et al. The use of bone marrow aspirations and lumbar punctures at the time of diagnosis of retinoblastoma. *J Clin Oncol* 1989;7:140–143.
269. Pratt CB, Crom DB, Magill L, et al. Skeletal scintigraphy in patients with bilateral retinoblastoma. *Cancer* 1990;65:26–28.
270. Martin H, Reese A. Treatment of retinoblastoma (retinal glioma) surgically and by irradiation. *Arch Ophthalmol* 1942;27.
271. Reese AB, Ellsworth RM. Management of Retinoblastoma. *Ann N Y Acad Sci* 1964;114:958–962.
272. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. *Ophthalmol Clin North Am* 2005;18:41–53.
273. Pratt CB, Fontanesi J, Lu X, et al. Proposal for a new staging scheme for intraocular and extraocular retinoblastoma based on an analysis of 103 globes. *Oncologist* 1997;2:1–5.
274. Chantada G, Doz F, Antoneli CB, et al. A proposal for an international retinoblastoma staging system. *Pediatr Blood Cancer* 2006;47:801–805.
275. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction for unilateral retinoblastoma. *Arch Ophthalmol* 2002;120:1653–1658.
276. Stannard C, Lipper S, Sealy R, et al. Retinoblastoma: correlation of invasion of the optic nerve and choroid with prognosis and metastases. *Br J Ophthalmol* 1979;63:560–570.
277. Fountain TR, Goldberger S, Murphree AL. Orbital development after enucleation in early childhood. *Ophthal Plast Reconstr Surg* 1999;15:32–36.
278. Shields JA, Glazer LC, Mieler WF, et al. Comparison of xenon arc and argon laser photocoagulation in the treatment of choroidal melanomas. *Am J Ophthalmol* 1990;109:647–655.
279. Wilson MW, Haik BG, Liu T, et al. Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma. *Am J Ophthalmol* 2005;140:397–406.
280. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. *Am J Ophthalmol* 2002;133:657–664.
281. Shields JA, Parsons H, Shields CL, et al. The role of cryotherapy in the management of retinoblastoma. *Am J Ophthalmol* 1989;108:260–264.
282. Shields CL, Mashayekhi A, Sun H, et al. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. *Ophthalmology* 2006;113:2087–2092.
283. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. *Ophthalmology* 2001;108:2116–2121.
284. Hernandez JC, Brady LW, Shields JA, et al. External beam radiation for retinoblastoma: results, patterns of failure, and a proposal for treatment guidelines. *Int J Radiat Oncol Biol Phys* 1996;35:125–132.
285. Kaste SC, Chen G, Fontanesi J, et al. Orbital development in long-term survivors of retinoblastoma. *J Clin Oncol* 1997;15:1183–1189.
286. Lee CT, Bilton SD, Farniglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? *Int J Radiat Oncol Biol Phys* 2005;63:362–372.
287. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. *J Natl Cancer Inst* 2008;100:1771–1779.
288. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. *J Clin Oncol* 2005;23:2272–2279.
289. Pratt CB, Fontanesi J, Chenaille P, et al. Chemotherapy for extraocular retinoblastoma. *Pediatr Hematol Oncol* 1994;11:301–309.
290. Pratt CB, Crom DB, Howarth C. The use of chemotherapy for extraocular retinoblastoma. *Med Pediatr Oncol* 1985;13:330–333.
291. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. *J Clin Oncol* 2000;18:12–17.
292. Gombos DS, Kelly A, Coen PG, et al. Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. *Br J Ophthalmol* 2002;86:80–83.

293. Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. *Cancer* 2012;118:5663–5670.
294. Kunkele A, Jurklics C, Wieland R, et al. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre. *Br J Ophthalmol* 2013;97:1277–1283.
295. Aerts I, Sastre-Carax X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. *J Clin Oncol* 2013;31:1458–1463.
296. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. *J Clin Oncol* 2003;21:2019–2025.
297. Shields CL, Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. *Ophthalmology* 1997;104:2101–2111.
298. Chan HS, DeBoer G, Thiessen JJ, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. *Clin Cancer Res* 1996;2:1499–1508.
299. Chantada GL, Dunkel IJ, de Davila MT, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? *Br J Ophthalmol* 2004;88:1069–1073.
300. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. *Ophthalmology* 1999;106:1947–1950.
301. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. *Int J Clin Oncol* 2004;9:69–73.
302. Abramson DH, Dunkel IJ, Brodie SE, et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. *Ophthalmology* 2008;115:1398–1404.
303. Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. *Br J Ophthalmol* 2012;96:1078–1083.
304. Brennan RC, Federico S, Bradley C, et al. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. *Cancer Res* 2011;71:4205–4213.
305. Benavente CA, McEvoy JD, Findelstein D, et al. Cross-species genomic and epigenomic landscape of retinoblastoma. *Oncotarget* 2013;4:844–859.
306. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of metastatic retinoblastoma. *Ophthalmology* 2003;110:1237–1240.
307. Palma J, Sasso DF, Dufort G, et al. Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America. *Bone Marrow Transplant* 2012;47:522–527.
308. Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. *Bone Marrow Transplant* 2005;35:763–766.
309. Combos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? *Ophthalmology* 2007;114:1378–1383.
310. Weintraub M, Revel-Vilk S, Charit M, et al. Secondary acute myeloid leukemia after etoposide therapy for retinoblastoma. *J Pediatr Hematol Oncol* 2007;29:646–648.
311. Bhagat SP, Bass JK, White ST, et al. Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma. *Int J Pediatr Otorhinolaryngol* 2010;74:1156–1163.
312. Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. *J Clin Oncol* 2012;30:1034–1041.
313. Weintraub N, Rot I, Shoshani N, et al. Participation in daily activities and quality of life in survivors of retinoblastoma. *Pediatr Blood Cancer* 2011;56:590–594.
314. van Dijk J, Huisman J, Moll AC, et al. Health-related quality of life of child and adolescent retinoblastoma survivors in the Netherlands. *Health Qual Life Outcomes* 2007;5:65.
315. Gurney JG, Swensen, AR, Bulterys M. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG, et al., eds. *Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995*. Bethesda, MD: National Institute of Health; 1999: 99–110.
316. Heare T, Hensley MA, Dell'Orfano S. Bone tumors: osteosarcoma and Ewing's sarcoma. *Curr Opin Pediatr* 2009;21:365–372.
317. Bielack SS, Carrle D, Harges J, et al. Bone tumors in adolescents and young adults. *Curr Treat Options Oncol* 2008;9:67–80.
318. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. *Cancer* 2009;115:1531–1543.
319. Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. *N Engl J Med* 1987;317:588–593.
320. Hawkins MM, Wilsom LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. *J Natl Cancer Inst* 1996;88:270–278.
321. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. *Int J Cancer* 2009;125:229–234.
322. MacCarthy A, Bayne AM, Brownbill PA, et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. *Br J Cancer* 2013;108:2455–2463.
323. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? *Ann Intern Med* 1969;71:747–752.
324. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990;250:1233–1238.
325. Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. *N Engl J Med* 1992;326:1301–1308.
326. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. *J Clin Oncol* 1994;12:925–930.
327. Wang LL, Levy ML, Lewis RA, et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. *Am J Med Genet* 2001;102:11–17.
328. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. *J Natl Cancer Inst* 2003;95:669–674.
329. Araki N, Uchida A, Kimura T, et al. Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. *Clin Orthop Relat Res* 1991;271–277.
330. Scholz RB, Kabisch H, Weber B, et al. Studies of the RB1 gene and the p53 gene in human osteosarcomas. *Pediatr Hematol Oncol* 1992;9:125–137.
331. Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. *Cancer Res* 1994;54:3042–3048.
332. Maeldandsmo GM, Berner JM, Florenes VA, et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas—relationship to amplification and mRNA levels of CDK4 and CCND1. *Br J Cancer* 1995;72:393–398.
333. Miller CW, Aslo A, Won A, et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. *J Cancer Res Clin Oncol* 1996;122:559–565.
334. Wei G, Lonardo F, Ueda T, et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4 gene alterations and mapping of 12q13 amplicons. *Int J Cancer* 1999;80:199–204.
335. Gokgoz N, Wunder JS, Mousset S, et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. *Cancer* 2001;92:2181–2189.
336. Lopez-Guerrero JA, Lopez-Gines C, Pellin A, et al. Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. *Diagn Mol Pathol* 2004;13:81–91.
337. Overholzer M, Rao PH, Favis R, et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. *Proc Natl Acad Sci U S A* 2003;100:11547–11552.
338. Nishijo K, Nakayama T, Aoyama T, et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. *Int J Cancer* 2004;111:367–372.
339. Bacci G, Ferrari S, Longhi A, et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. *Acta Orthop Scand* 2003;74:449–454.
340. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. *Cancer* 2006;106:1154–1161.
341. Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. *Cancer* 1979;43:2178–2181.
342. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. *Clin Orthop Relat Res* 1991;8–14.
343. Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: state of the art. *Cancer Treat Rev* 2006;32:423–436.
344. Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. *Pediatr Blood Cancer* 2008;51:163–170.
345. Byun BH, Kong CB, Lim I, et al. Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma. *Skeletal Radiol* 2013;42:1673–1681.
346. Quartuccio N, Treglia G, Salsano M, et al. The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. *Radiol Oncol* 2013;47:97–102.
347. Denecke T, Hundsdoerfer P, Misch D, et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. *Eur J Nucl Med Mol Imaging* 2010;37:1842–1853.
348. Kong CB, Byun BH, Lim I, et al. <sup>18</sup>F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. *Eur J Nucl Med Mol Imaging* 2013;40:728–736.
349. Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 2009;20:137–139.
350. Peabody TD, Simon MA. Making the diagnosis: keys to a successful biopsy in children with bone and soft-tissue tumors. *Orthop Clin North Am* 1996;27:453–459.
351. Inwards CY, Unni KK. Classification and grading of bone sarcomas. *Hematol Oncol Clin North Am* 1995;9:545–569.
352. Papagelopoulos PJ, Galanis EC, Vlastou C, et al. Current concepts in the evaluation and treatment of osteosarcoma. *Orthopedics* 2000;23:858–867.



353. Yarmish G, Klein MJ, Landa J, et al. Imaging characteristics of primary osteosarcoma: nonconventional subtypes. *Radiographics* 2010;30:1653–1672.
354. Antonescu CR, Huvos AG. Low-grade osteogenic sarcoma arising in medullary and surface osseous locations. *Am J Clin Pathol* 2000;114:S90–S103.
355. Revell MP, Deshmukh N, Grimer RJ, et al. Periosteal osteosarcoma: a review of 17 cases with mean follow-up of 52 months. *Sarcoma* 2002;6:123–130.
356. Nakajima H, Sim FH, Bond JR, et al. Small cell osteosarcoma of bone. Review of 72 cases. *Cancer* 1997;79:2095–2106.
357. Dragoescu E, Jackson-Cook C, Domson G, et al. Small cell osteosarcoma with Ewing sarcoma breakpoint region 1 gene rearrangement detected by interphase fluorescence in situ hybridization. *Ann Diagn Pathol* 2013;17:377–382.
358. Bane BL, Evans HL, Ro JY, et al. Extraskelatal osteosarcoma. A clinicopathologic review of 26 cases. *Cancer* 1990;65:2762–2770.
359. Bridge JA, Nelson M, McComb E, et al. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. *Cancer Genet Cytogenet* 1997;95:74–87.
360. Lau CC, Harris CP, Lu XY, et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. *Genes Chromosomes Cancer* 2004;39:11–21.
361. Sadikovic B, Yoshimoto M, Chilton-MacNeill S, et al. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. *Hum Mol Genet* 2009;18:1962–1975.
362. Selvarajah S, Yoshimoto M, Ludovski O, et al. Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. *Cytogenet Genome Res* 2008;122:5–15.
363. Squire JA, Pei J, Marrano P, et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. *Genes Chromosomes Cancer* 2003;38:215–225.
364. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. *Cancer* 1993;72:3227–3238.
365. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. *N Engl J Med* 1986;314:1600–1606.
366. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. *J Clin Oncol* 1992;10:5–15.
367. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. *J Clin Oncol* 1987;5:21–26.
368. Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. *Cancer* 1979;43:2163–2177.
369. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. *J Clin Oncol* 2003;21:1574–1580.
370. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. *J Pediatr Hematol Oncol* 2003;25:845–853.
371. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. *J Clin Oncol* 2005;23:8845–8852.
372. Muller CR, Smeland S, Bauer HC, et al. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. *Acta Oncol* 2005;44:475–480.
373. Whelan J, Patterson D, Perisoglou M, et al. The role of interferons in the treatment of osteosarcoma. *Pediatr Blood Cancer* 2010;54:350–354.
374. Bielack S, Smeland S, Whelan J, et al. MAP plus maintenance pegylated interferon alpha-2b (MAPIn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization. *Ann Meet Am Soc Clin Oncol* 2013;31:Abstract No. LBA10504.
375. Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. *J Clin Oncol* 1998;16:3641–3648.
376. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. *J Clin Oncol* 2002;20:426–433.
377. Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. *Ann Oncol* 2003;14:1126–1134.
378. Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. *J Clin Oncol* 2003;21:2011–2018.
379. Bacci G, Briccoli A, Mercuri M, et al. Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. *J Chemother* 1998;10:69–76.
380. Harting MT, Blakely ML. Management of osteosarcoma pulmonary metastases. *Semin Pediatr Surg* 2006;15:25–29.
381. Harting MT, Blakely ML, Jaffe N, et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. *J Pediatr Surg* 2006;41:194–199.
382. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. *J Clin Oncol* 2002;20:776–790.
383. Bacci G, Longhi A, Bertoni F, et al. Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients. *Acta Orthop* 2006;77:938–943.
384. Anderson PM, Meyers P, Kleinerman E, et al. Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. *Pediatr Blood Cancer* 2014;61:238–244.
385. Goldsby RE, Fan TM, Villaluna D, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. *Eur J Cancer* 2013;49:2384–2391.
386. Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. *Cancer* 2011;117:1736–1744.
387. Gill J, Ahluwalia MK, Celler D, et al. New targets and approaches in osteosarcoma. *Pharmacol Ther* 2013;137:89–99.
388. Bacci G, Ferrari S, Longhi A, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. *Eur J Cancer* 2001;37:32–38.
389. Mason GE, Aung L, Gall S, et al. Quality of life following amputation or limb preservation in patients with lower extremity bone sarcoma. *Front Oncol* 2013;3:210.
390. Ginsberg JP, Rai SN, Carlson CA, et al. A comparative analysis of functional outcomes in adolescents and young adults with lower-extremity bone sarcoma. *Pediatr Blood Cancer* 2007;49:964–969.
391. DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. *Int J Radiat Oncol Biol Phys* 2005;61:492–498.
392. Mahajan A, Woo SY, Konguth DG, et al. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. *Pediatr Blood Cancer* 2008;50:976–982.
393. Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. *J Surg Oncol* 2007;96:118–123.
394. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. *Cancer* 2003;98:2447–2456.
395. Rodriguez-Galindo C, Shah N, McCarville MB, et al. Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970-2000). *Cancer* 2004;100:1928–1935.
396. Berrak SG, Pearson M, Berberoglu S, et al. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. *Pediatr Blood Cancer* 2005;44:215–219.
397. Aad G, Abbott B, Abdallah J, et al. Search for pair production of a new b' quark that decays into a Z boson and a bottom quark with the ATLAS detector. *Phys Rev Lett* 2012;109:071801.
398. Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. *J Clin Oncol* 2004;22:1706–1712.
399. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. *Cancer* 2008;113:419–425.
400. Rodriguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. *J Pediatr Hematol Oncol* 2002;24:250–255.
401. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. *Ann Oncol* 2012;23:508–516.
402. Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. *Eur J Cancer* 2011;47:895–902.
403. Leary SE, Wozniak AW, Billups CA, et al. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience. *Cancer* 2013;119:2645–2653.
404. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. *J Clin Oncol* 1994;12:423–431.
405. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma: The Memorial Hospital experience. *Cancer* 1992;69:698–708.
406. Meyer WH, Kun L, Marina N, et al. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. *J Clin Oncol* 1992;10:1737–1742.
407. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children's Oncology Group. *J Clin Oncol* 2008;26:633–638.
408. de Alava E, Lessnick SL, Sorensen PH. In: Fletcher CDM, Bridge JA, Hogendoom PC, et al., eds. *WHO Classification of Tumours of Soft Tissue and Bone*. Lyon: International Agency of Research on Cancer; 2013:305–309.
409. Applebaum MA, Worch J, Matthay KK, et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. *Cancer* 2011;117:3027–3032.
410. Potluyan G, France KA, Carlson MR, et al. Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors. *Lab Invest* 2008;88:1291–1302.

411. Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. *Cancer Res* 2008;68:2176–2185.
412. Tirode F, Laud-Duval K, Prieur A, et al. Mesenchymal stem cell features of Ewing tumors. *Cancer Cell* 2007;11:421–429.
413. Dela Cruz FS. Cancer stem cells in pediatric sarcomas. *Front Oncol* 2013;3:168.
414. Lazar A, Abruzzo LV, Pollock RE, et al. Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. *Arch Pathol Lab Med* 2006;130:1199–1207.
415. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. *Cancer Lett* 2007;254:1–10.
416. Sankar S, Lessnick SL. Promiscuous partnerships in Ewing's sarcoma. *Cancer Genet* 2011;204:351–365.
417. Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. *J Clin Oncol* 2010;28:1982–1988.
418. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2010;28:1989–1994.
419. Joo J, Christensen L, Warner K, et al. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. *PLoS One* 2009;4:e7608.
420. Zwemer JP, Joo J, Warner KL, et al. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. *Oncogene* 2008;27:3282–3291.
421. Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. *Nat Med* 1983;15:750–756.
422. Geryk-Hall M, Hughes DP. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. *Curr Oncol Rep* 2009;11:446–453.
423. Kolb EA, Gorlick R. Development of IGF-IR Inhibitors in Pediatric Sarcomas. *Curr Oncol Rep* 2009;11:307–313.
424. Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. *Cancer Res* 2009;69:7662–7671.
425. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. *Oncogene* 2003;22:9282–9287.
426. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-IR antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase I expansion cohort study. *Lancet Oncol* 2010;11:129–135.
427. Sneppen O, Hansen LM. Presenting symptoms and treatment delay in osteosarcoma and Ewing's sarcoma. *Acta Radiol Oncol* 1984;23:159–162.
428. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. *J Bone Joint Surg Am* 2000;82:667–674.
429. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. *Oncologist* 2006;11:503–519.
430. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. *Med Pediatr Oncol* 2003;40:276–287.
431. Farley FA, Healey JH, Caparros-Sison B, et al. Lactase dehydrogenase as a tumor marker for recurrent disease in Ewing's sarcoma. *Cancer* 1987;59:1245–1248.
432. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. *AJR Am J Roentgenol* 2001;177:229–236.
433. Volker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. *J Clin Oncol* 2007;25:5435–5441.
434. Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. *Eur J Nucl Med* 2000;27:1305–1311.
435. Hawkins DS, Scheutze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. *J Clin Oncol* 2005;23:8828–8834.
436. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. *Ann Oncol* 1998;9:275–281.
437. Riopel M, Dickman PS, Link MP, et al. MIC2 analysis in pediatric lymphomas and leukemias. *Hum Pathol* 1994;25:396–399.
438. Ozdemirli M, Fanburg-Smith JC, Hartmann DP, et al. Differentiating lymphoblastic lymphoma and Ewing's sarcoma: lymphocyte markers and gene rearrangement. *Mod Pathol* 2001;14:1175–1182.
439. Granter SR, Renshaw AA, Fletcher CD, et al. CD99 reactivity in mesenchymal chondrosarcoma. *Hum Pathol* 1996;27:1273–1276.
440. Pelmus M, Guillou L, Hostein I, et al. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18) (SYT-SSX)-positive cases. *Am J Surg Pathol* 2002;26:1434–1440.
441. Balamuth NJ, Womer RB. Ewing's sarcoma. *Lancet Oncol* 2010;11:184–192.
442. Bacci G, Mercuri M, Longhi A, et al. Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. *Eur J Cancer* 2002;38:2243–2251.
443. Burgert EO Jr, Nesbit ME, Garmsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. *J Clin Oncol* 1990;8:1514–1524.
444. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. *J Clin Oncol* 1998;16:3628–3633.
445. Craft AW, Cotterill SJ, Bullimore JA, et al. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. *Eur J Cancer* 1997;33:1061–1069.
446. Granowetter L, Worner R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. *J Clin Oncol* 2009;27:2536–2541.
447. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. *N Engl J Med* 2003;348:694–701.
448. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. *Cancer* 1988;61:23–32.
449. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. *J Clin Oncol* 1990;8:1664–1674.
450. Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). *Br J Cancer* 2001;85:1646–1654.
451. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. *J Clin Oncol* 2001;19:1818–1829.
452. Rosen G, Caparros B, Mosende C, et al. Curability of Ewing's sarcoma and considerations for future therapeutic trials. *Cancer* 1978;41:888–899.
453. Gaspar N, Rey A, Berard PM, et al. Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study. *Eur J Cancer* 2012;48:1376–1385.
454. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2012;30:4148–4154.
455. Obata H, Ueda T, Kawai A, et al. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. *Cancer* 2007;109:767–775.
456. Wexler LH, DeLaney TF, Tsokos M, et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. *Cancer* 1996;78:901–911.
457. Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. *Pediatr Blood Cancer* 2006;47:22–29.
458. Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy—a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2007;49:894–900.
459. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children's Cancer Group and Pediatric Oncology Group study. *J Clin Oncol* 2004;22:2873–2876.
460. Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. *Cancer* 1990;66:887–893.
461. Ladenstein R, Potschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. *J Clin Oncol* 2010;28:3284–3291.
462. Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—a report from the Children's Oncology Group. *J Clin Oncol* 2006;24:152–159.
463. Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. *J Clin Oncol* 1999;17:180–190.
464. Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. *Pediatr Blood Cancer* 2008;51:334–338.
465. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979–1999. *Cancer* 2002;94:561–569.
466. Shankar AG, Ashley S, Craft AW, et al. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. *Med Pediatr Oncol* 2003;40:141–147.
467. McLean TW, Hartel C, Young ML, et al. Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: the Dana-Farber Cancer Institute/Children's Hospital experience. *J Pediatr Hematol Oncol* 1999;21:486–493.



468. Hunold A, Weddelling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. *Pediatr Blood Cancer* 2006;47:795–800.
469. Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. *J Clin Oncol* 1995;13:2796–2804.
470. Saylor RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. *J Clin Oncol* 2001;19:3463–3469.
471. Casey DA, Wesler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. *Pediatr Blood Cancer* 2009;53:1029–1034.
472. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. *Pediatr Blood Cancer* 2007;48:132–139.
473. Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. *J Pediatr Hematol Oncol* 2001;23:30–38.
474. Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase III study. *J Pediatr Hematol Oncol* 1995;17:265–269.
475. Marina NM, Rodman J, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. *J Clin Oncol* 1993;11:554–560.
476. Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. *J Pediatr Hematol Oncol* 2009;31:723–729.
477. Rosenthal J, Pawlowska AB. High-dose chemotherapy and stem cell rescue for high-risk Ewing's family of tumors. *Expert Rev Anticancer Ther* 2001;1:251–262.
478. Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. *Bone Marrow Transplant* 1995;15:697–705.
479. Dunst J, Schuck A. Role of radiotherapy in Ewing tumors. *Pediatr Blood Cancer* 2004;42:465–470.
480. Shamberger RC, Tarbell NJ, Perez-Atayde AR, et al. Malignant small round cell tumor (Ewing's-PNET) of the chest wall in children. *J Pediatr Surg* 1994;29:179–184.
481. Denbo JW, Shannon Orr W, Wu Y, et al. Timing of surgery and the role of adjuvant radiotherapy in Ewing sarcoma of the chest wall: a single-institution experience. *Ann Surg Oncol* 2012;19:3809–3815.
482. Shamberger RC, LaQuaglia MP, Krailo MD, et al. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection. *J Thorac Cardiovasc Surg* 2000;119:1154–1161.
483. Shamberger RC, LaQuaglia MP, Gebhardt MC, et al. Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. *Ann Surg* 2003;238:563–567.
484. Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. *Int J Radiat Oncol Biol Phys* 2003;55:168–177.
485. Indelicato DJ, Keole SR, Shahlacae AH, et al. Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. *Int J Radiat Oncol Biol Phys* 2008;72:871–877.
486. Krasin MJ, Rodriguez-Galindo C, Billups CA, et al. Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. *Int J Radiat Oncol Biol Phys* 2004;60:830–838.
487. Rodriguez-Galindo C, Navid F, Liu T, et al. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. *Ann Oncol* 2008;19:814–820.
488. Donaldson SS, Torrey M, Link MP, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. *Int J Radiat Oncol Biol Phys* 1998;42:125–135.
489. Kuttesch JF Jr, Waxler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. *J Clin Oncol* 1996;14:2818–2825.
490. Paulussen M, Ahrens S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. *J Clin Oncol* 1998;16:3044–3052.
491. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. *J Clin Oncol* 2000;18:3108–3114.
492. Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. *J Clin Oncol* 2001;19:2812–2820.
493. Picci P, Bohling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. *J Clin Oncol* 1997;15:1553–1559.
494. Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. *J Bone Joint Surg Am* 1998;80:1020–1033.
495. Cheung IY, Feng Y, Danis K, et al. Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. *Clin Cancer Res* 2007;13:6978–6983.
496. Schaefer KL, Eisenacher M, Braun Y, et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. *Eur J Cancer* 2008;44:699–709.
497. Ognjanovic S, Linabery AM, Charbonneau B, et al. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. *Cancer* 2009;115:4218–4226.
498. Ognjanovic S, Olivier M, Bergemann TL, et al. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. *Cancer* 2012;118:1387–1396.
499. Gripp KW, SCott CI Jr, Nicholson L, et al. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. *Am J Med Genet* 2002;108:80–87.
500. Smith AC, Squire JA, Thorner P, et al. Association of alveolar rhabdomyosarcoma with the Beckwith-Wiedemann syndrome. *Pediatr Dev Pathol* 2001;4:550–558.
501. Sung L, Anderson JR, Arndt C, et al. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the intergroup Rhabdomyosarcoma study IV. *J Pediatr* 2004;144:666–668.
502. Doros L, Yang J, Dehner L, et al. DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome. *Pediatr Blood Cancer* 2012;59:558–560.
503. Grufferman S, Schwartz AG, Ruymann FB, et al. Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. *Cancer Causes Control* 1993;4:217–224.
504. Ognjanovic S, Carozza SE, Chow EJ, et al. Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype. *Br J Cancer* 2010;102:227–231.
505. Von Behren J, Spector LG, Mueller BA, et al. Birth order and risk of childhood cancer: A pooled analysis from five US States. *Int J Cancer* 2011;128:2709–2716.
506. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. *J Clin Oncol* 2005;21:78–84.
507. Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification—an Intergroup Rhabdomyosarcoma Study. *Cancer* 1995;76:1073–1085.
508. Fletcher C, Bridge JA, Hogendoorn P, et al., eds. *WHO Classification of Tumors of Soft Tissue and Bone*. 4th ed. Lyon: IARC; 2013: 127–134.
509. Qualman S, Lynch J, Bridge J, et al. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Cancer* 2008;113:3242–3247.
510. Rudzinski ER, Teot LA, Anderson JR, et al. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Am J Clin Pathol* 2013;140:82–90.
511. Pappo AS, Shapiro DN, Crist WM, et al. Biology and therapy of pediatric rhabdomyosarcoma. *J Clin Oncol* 1995;13:2123–2139.
512. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. *J Clin Oncol* 2001;19:3091–3102.
513. Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. *Arch Pathol Lab Med* 2006;130:1454–1465.
514. Chiles MC, Parham DM, Qualman SJ, et al. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group. *Pediatr Dev Pathol* 2005;8:141.
515. Scrabble H, Cavanee W, Ghavimi F, et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. *Proc Natl Acad Sci U S A* 1989;86:7480–7484.
516. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. *J Clin Invest* 1994;94:445–448.
517. Williamson D, Missiaglia E, de Reynies A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. *J Clin Oncol* 2010;28:2151–2158.
518. Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. *Genes Chromosomes Cancer* 2000;27:337–344.
519. Paulson V, Chandler G, Rakheja D, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. *Genes Chromosomes and Cancer* 2011;50:397–408.
520. Shukla N, Ameer N, Yilmaz I, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. *Clin Cancer Res* 2012;18:748–757.
521. van Gaal JC, Flucke UE, Roeffen MH, et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. *J Clin Oncol* 2012;30:308–315.

522. Newton WA Jr, Soule EH, Hamoudi AB, et al. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. *J Clin Oncol* 1988;6:67–75.
523. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. *J Pediatr Hematol Oncol* 1997;19:483–491.
524. Williamson D, Ly YJ, Gordon T, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. *J Clin Oncol* 2005;23:880–888.
525. Missiaglia E, Williamson D, Chisholm J, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. *J Clin Oncol* 2012;30:1670–1677.
526. Flamant F, Couanet D, McDowell H. *Rhabdomyosarcoma in Children: Clinical Symptoms, Diagnosis, and Staging*. Boca Raton, FL: CRC Press; 1991.
527. Spunt SL, Lobe TE, Pappo AS, et al. Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma. *J Pediatr Surg* 2000;35:309–316.
528. Weiss AR, Lyden ER, Anderson JR, et al. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. *J Clin Oncol* 2013;31:3226–3232.
529. Federico SM, Spunt SL, Krasin MJ, et al. Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. *Pediatr Blood Cancer* 2013;60:1128–1134.
530. Dharmarajan KV, Wexler LH, Gavane S, et al. Positron emission tomography (PET) evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma. *Int J Radiat Oncol Biol Phys* 2012;84:996–1002.
531. Spunt SL, Anderson JR, Teot LA, et al. Routine brain imaging is unwarranted in asymptomatic patients with rhabdomyosarcoma arising outside of the head and neck region that is metastatic at diagnosis: a report from the Intergroup Rhabdomyosarcoma Study Group. *Cancer* 2001;92:121–125.
532. Wiener ES, Anderson JR, Ojimba JJ, et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? *Semin Pediatr Surg* 2001;10:146–152.
533. De Corti F, Dall'Igna P, Bisogno G, et al. Sentinel node biopsy in pediatric soft tissue sarcomas of extremities. *Pediatr Blood Cancer* 2009;52:51–54.
534. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. *Cancer* 1988;61:209–220.
535. Lawrence W Jr, Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. *Pediatric Oncology Group. Cancer* 1997;80:1165–1170.
536. Wexler LH, Meyer WH, Helman LJ. Rhabdomyosarcoma. In: Poplack DG, Plzso PA, eds. *Principles and Practice of Pediatric Oncology*. Philadelphia: Lippincott Williams and Wilkins; 2011: 923–953.
537. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. *Pediatr Blood Cancer* 2012;59:5–10.
538. Meza JL, Anderson J, Pappo AS, et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. *J Clin Oncol* 2006;24:3844–3851.
539. Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *J Clin Oncol* 2011;29:1312–1318.
540. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. *J Clin Oncol* 2009;27:5182–5188.
541. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European Cooperative Groups. *J Clin Oncol* 2008;26:2384–2389.
542. Skapek SX, Anderson J, Barr FG, et al. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report. *Pediatr Blood Cancer* 2013;60:1411–1417.
543. Hays DM, Lawrence W Jr, Wharam M, et al. Primary reexcision for patients with 'microscopic residual' tumor following initial excision of sarcomas of trunk and extremity sites. *J Pediatr Surg* 1989;24:5–10.
544. Viswanathan AN, Grier HE, Litman HJ, et al. Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy. *Int J Radiat Oncol Biol Phys* 2004;58:1208–1214.
545. Cecchetto G, Bisogno G, De Corti F, et al. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: the experience of the Italian Cooperative Group studies. *Cancer* 2007;110:2561–2567.
546. Raney RB, Anderson JR, Brown KL, et al. Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2010;55:612–616.
547. Lin C, Donaldson SS, Meza JL, et al. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803—a report from the Children's Oncology Group. *Int J Radiat Oncol Biol Phys* 2012;82:1764–1770.
548. Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma—a report from the IRSG. *Int J Radiat Oncol Biol Phys* 2001;51:718–728.
549. Breneman J, Meza J, Donaldson SS, et al. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. *Int J Radiat Oncol Biol Phys* 2012;83:720–726.
550. Walterhouse DO, Meza JL, Breneman JC, et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. *Pediatr Blood Cancer* 2011;57:76–83.
551. Oberlin O, Rey A, Sanchez de Toledo J, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT195 study. *J Clin Oncol* 2012;30:2457–2465.
552. Lager JJ, Lyden ER, Anderson JR, et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *J Clin Oncol* 2006;24:3415–3422.
553. Carli M, Colombatti R, Oberlin O, et al. European Intergroup Studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. *J Clin Oncol* 2004;22:4735–4742.
554. Kolb EA, Gorlick R, Lock R, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2011;56:595–603.
555. Keir ST, Maris JM, Reynolds CP, et al. Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2013;60:783–790.
556. Chisholm JC, Marandet J, Rey A, et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. *J Clin Oncol* 2011;29:1319–1325.
557. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. *J Clin Oncol* 1999;17:3487–3493.
558. Bulterys M, Goodman M, Smith M, Buckley J. In: Ries LAG, Smith MA, Gurney JG, et al., eds. *Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995*. Bethesda, MD: National Cancer Institute; 1999.
559. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). *Cancer* 2008;112:416–432.
560. Spector LG, Birch J. The epidemiology of hepatoblastoma. *Pediatr Blood Cancer* 2012;59:776–779.
561. Darbari A, Sabin KM, Shapiro CN, et al. Epidemiology of primary hepatic malignancies in U.S. children. *Hepatology* 2003;38:560–566.
562. Finegold MJ, Egler RA, Goss JA, et al. Liver tumors: pediatric population. *Liver Transpl* 2008;14:1545–1556.
563. Litten JB, Tomlinson GE. Liver tumors in children. *Oncologist* 2008;13:812–820.
564. Ikeda H, Hacidanda Y, Tanimura M, et al. Development of unfavorable hepatoblastoma in children of very low birth weight: results of a surgical and pathologic review. *Cancer* 1998;82:1789–1796.
565. Reynolds P, Urayama KY, Von Behren J, et al. Birth characteristics and hepatoblastoma risk in young children. *Cancer* 2004;100:1070–1076.
566. Hirschman BA, Pollock BH, Tomlinson GE. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. *J Pediatr* 2005;147:263–266.
567. Sanders RP, Furman WL. Familial adenomatous polyposis in two brothers with hepatoblastoma: implications for diagnosis and screening. *Pediatr Blood Cancer* 2006;47:851–854.
568. Hoyne HE, Seaver LH, Jones KL, et al. Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. *Am J Med Genet* 1998;79:274–278.
569. Mariyama K, Ikeda H, Koizumi T. Hepatoblastoma associated with trisomy 18 syndrome: a case report and a review of the literature. *Pediatr Int* 2001;43:302–305.
570. Kitanovski L, Ovcak Z, Jazbec J. Multifocal hepatoblastoma in a 6-month-old girl with trisomy 18: a case report. *J Med Case Rep* 2009;3:8319.
571. Tomlinson GE, Kappler R. Genetics and epigenetics of hepatoblastoma. *Pediatr Blood Cancer* 2012;59:785–792.
572. Giardiello FM, Offerhaus GJ, Krush AJ, et al. Risk of hepatoblastoma in familial adenomatous polyposis. *J Pediatr* 1991;119:766–768.
573. Aretz S, Koch A, Uhlhaas S, et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? *Pediatr Blood Cancer* 2006;47:811–818.
574. Tomlinson GE, Douglass EC, Pollock BH, et al. Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21. *Genes Chromosomes Cancer* 2005;44:177–184.

575. Parada LA, Limon J, Illiszko M, et al. Cytogenetics of hepatoblastoma: further characterization of 1q rearrangements by fluorescence in situ hybridization: an international collaborative study. *Med Surg Oncol* 2000;34:165–170.
576. Schneider NR, Cooley LD, Finegold MJ, et al. The first recurring chromosome translocation in hepatoblastoma: der(4)t(1;4)(q12;q34). *Genes Chromosomes Cancer* 1997;19:291–294.
577. Tanimura M, Matsui I, Abe J, et al. Increased risk of hepatoblastoma among immature children with a lower birth weight. *Cancer Res* 1998;58:3032–3035.
578. Spector LG, Feusner JH, Ross JA. Hepatoblastoma and low birth weight. *Pediatr Blood Cancer* 2004;43:706.
579. Fiegel HC, Gluer S, Roth B, et al. Stem-like cells in human hepatoblastoma. *J Histochem Cytochem* 2004;52:1495–1501.
580. Ruck P, Xiao JC. Stem-like cells in hepatoblastoma. *Med Pediatr Oncol* 2002;39:504–507.
581. Lopez-Terrada D, Alaggio R, de Davila MT, et al. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. *Mod Pathol* 2014;27:472–291.
582. Malogolowkin MH, Katzenstein HM, Meyers RL, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group. *J Clin Oncol* 2011;29:3301–3306.
583. De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. *Eur J Cancer* 2008;44:545–550.
584. Russo P, Biegel JA. SMARCB1/INI1 alterations and hepatoblastoma: another extrarenal rhabdoid tumor revealed? *Pediatr Blood Cancer* 2009;52:312–313.
585. Navarro C, Corretger JM, Sancho A, et al. Paraneoplastic precocious puberty. Report of a new case with hepatoblastoma and review of the literature. *Cancer* 1985;56:1725–1729.
586. Shafford EA, Pritchard J. Extreme thrombocytosis as a diagnostic clue to hepatoblastoma. *Arch Dis Child* 1993;69:171.
587. Komura E, Matsumura T, Kato T, et al. Thrombopoietin in patients with hepatoblastoma. *Stem Cells* 1998;16:329–333.
588. Katzenstein HM, Krailo MD, Malogolowkin MG, et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. *J Clin Oncol* 2002;20:2789–2797.
589. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. *J Clin Oncol* 2002;20:2798–2804.
590. Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group. *J Clin Oncol* 1997;15:1190–1197.
591. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. *Cancer* 2002;95:172–182.
592. Cistaro A, Treglia G, Pagano M, et al. A comparison between (18) F-FDG PET/CT imaging and biological and radiological findings in restaging of hepatoblastoma patients. *Biomed Res Int* 2013;2013:709037.
593. McCarville MB, Roebuck DJ. Diagnosis and staging of hepatoblastoma: imaging aspects. *Pediatr Blood Cancer* 2012;59:793–799.
594. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. *J Clin Oncol* 2000;18:2665–2675.
595. Meyers RL, Rowland JR, Krailo M, et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2009;53:1016–1022.
596. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma—results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. *Eur J Cancer* 2000;36:1418–1425.
597. Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. *Pediatr Radiol* 2007;37:123–132.
598. Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. *J Clin Oncol* 2005;23:1245–1252.
599. Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era—recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOP). *Eur J Cancer* 2005;41:1031–1036.
600. Maibach R, Roebuck D, Brugieres L, et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. *Eur J Cancer* 2012;48:1543–1549.
601. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, et al. Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors. *Pediatr Blood Cancer* 2009;52:328–334.
602. Arnaoutakis DJ, Mavros MN, Shen F, et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. *Ann Surg Oncol* 2014;21:147–154.
603. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012;379:1245–1255.
604. Tiao GM, Bobey N, Allen S, et al. The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation. *J Pediatr* 2005;146:204–211.
605. Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. *Cancer* 2002;94:1111–1120.
606. Kishi Y, Hasegawa K, Sugawara Y, et al. Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. *Int J Hepatol* 2001;2011:728103.
607. Chow PK. Resection for hepatocellular carcinoma: is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria? *J Gastroenterol Hepatol* 2012;27:452–457.
608. Chen JC, Chen CC, Chen WJ, et al. Hepatocellular carcinoma in children: clinical review and comparison with adult cases. *J Pediatr Surg* 1998;33:1350–1354.
609. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach—results of the first prospective study of the International Society of Pediatric Oncology. *J Clin Oncol* 2000;18:3819–3828.
610. Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology—SIOPEL 2. *Eur J Cancer* 2004;40:411–421.
611. Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. *Pediatr Blood Cancer* 2004;42:74–83.
612. Faraj W, Dar F, Marangoni G, et al. Liver transplantation for hepatoblastoma. *Liver transplantation* 2008;14:1614–1619.
613. Hery G, Franchi-Abella S, Habes D, et al. Initial liver transplantation for unresectable hepatoblastoma after chemotherapy. *Pediatr Blood Cancer* 2011;57:1270–1275.
614. Reyes JD, Carr B, Dvorchik I, et al. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. *J Pediatr* 2000;136:795–804.
615. Pham TH, Iqbal CW, Grams JM, et al. Outcomes of primary liver cancer in children: an appraisal of experience. *J Pediatr Surg* 2007;42:834–839.
616. Semvis S, Karakayali H, Ozcay F, et al. Liver transplantation for hepatocellular carcinoma in children. *Pediatr Transplant* 2008;12:52–56.
617. Ismail H, Broniszczak D, Kalicinski P, et al. Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? *Pediatr Transplant* 2009;13:682–692.
618. Romano F, Stroppo P, Bravi M, et al. Favorable outcome of primary liver transplantation in children with cirrhosis and hepatocellular carcinoma. *Pediatr Transplant* 2011;15:573–579.
619. McAteer JP, Goldin AB, Healey PJ, et al. Surgical treatment of primary liver tumors in children: Outcomes analysis of resection and transplantation in the SEER database. *Pediatr Transplant* 2013;17:744–750.
620. Ni JY, Liu SS, Xu LF, et al. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. *J Cancer Res Clin Oncol* 2013;139:653–659.
621. Malogolowkin MH, Stanley P, Steele DA, et al. Feasibility and toxicity of chemoembolization for children with liver tumors. *J Clin Oncol* 2000;18:1279–1284.
622. Arcement CM, Towbin RB, Meza MP, et al. Intrahepatic chemoembolization in unresectable pediatric liver malignancies. *Pediatr Radiol* 2000;30:779–785.
623. Czauderna P, Zbrzezniak G, Narozanski W, et al. Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. *Pediatr Blood Cancer* 2006;46:825–828.
624. Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. *Int J Radiat Oncol Biol Phys* 2013;87:22–32.
625. Dawson LA. Overview: Where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? *Semin Radiat Oncol* 2011;21:241–246.
626. Habrand JL, Nehme D, Kalifa C, et al. Is there a place for radiation therapy in the management of hepatoblastomas and hepatocellular carcinomas in children? *Int J Radiat Oncol Biol Phys* 1992;23:525–531.
627. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. *N Engl J Med* 2009;361:1662–1670.
628. Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. *J Clin Oncol* 2010;28:2584–2590.
629. Zsiros J, Brugieres L, Brock P, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. *Lancet Oncol* 2013;14:834–842.



630. Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. *Lancet Oncol* 2000;1:94–100.
631. Evans AE, Land VJ, Newton WA, et al. Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma. *Cancer* 1982;50:821–826.
632. Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. *J Clin Oncol* 1993;11:96–99.
633. Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Children's Cancer Study Group. *J Clin Oncol* 1991;9:2167–2176.
634. von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and etoposide in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. *Eur J Cancer* 1997;33:1243–1249.
635. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. *J Clin Oncol* 2002;20:3438–3444.
636. Fuchs J, Bode U, von Schweinitz D, et al. Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94. *Klin Padiatr* 1999;211:305–309.
637. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. *J Clin Oncol* 1999;17:1815–1824.
638. Zsiros J, Brugieres L, Brock P, et al. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma—a phase II trial of the childhood liver tumour strategy group (SIOPEL). *Eur J Cancer* 2012;48:3456–3464.
639. Malogolowkin MH, Katzenstein H, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. *J Clin Oncol* 2006;24:2879–2884.
640. Malogolowkin MH, Katzenstein HM, Krailo M, et al. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. *J Clin Oncol* 2008;26:2379–2383.
641. Poynter JN, Amatruda JF, Ross JA. Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. *Cancer* 2010;116:4882–4891.
642. Olson TA, Schneider D, Perlman EJ. Germ cell tumors. In: Pizzo PA, Poplack DC, eds. *Principles and Practice of Pediatric Oncology*. Philadelphia: Lippincott Williams and Wilkins; 2011: 1045–1067.
643. Pettersson A, Richiardi L, Nordenskjold A, et al. Age at surgery for undescended testis and risk of testicular cancer. *N Engl J Med* 2007;356:1835–1841.
644. Schneider DT, Calaminus G, Koch S, et al. Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols. *Pediatr Blood Cancer* 2004;42:169–175.
645. Frazier AL, Rumcheva P, Olson T, et al. Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2008;50:746–751.
646. Einhorn LH. Chemotherapy of disseminated germ cell tumors. *Cancer* 1987;60:570–573.
647. Ablin AR, Krailo MD, Ramsay NK, et al. Results of treatment of malignant germ cell tumors in 93 children: a report from the Children's Cancer Study Group. *J Clin Oncol* 1991;9:1782–1792.
648. Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882. *J Clin Oncol* 2004;22:2691–2700.
649. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. *Cancer* 2005;104:841–847.
650. Malogolowkin MH, Krailo M, Marina N, et al. Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: A report of the children's oncology group (COG). *Pediatr Blood Cancer* 2013;60:1602–1605.
651. Rescorla FJ. Pediatric germ cell tumors. *Semin Pediatr Surg* 2012;21:51–60.
652. Altman RP, Randolph JG, Lilly JR. Sacrococcygeal teratoma: American Academy of Pediatrics Surgical Section Survey-1973. *J Pediatr Surg* 1974;9:389–398.
653. Rescorla FJ, Sawin RS, Coran AG, et al. Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Children's Cancer Group. *J Pediatr Surg* 1998;33:171–176.
654. Rescorla F, Billmore D, Stolar C, et al. The effect of cisplatin dose and surgical resection in children with malignant germ cell tumors at the sacrococcygeal region: a pediatric intergroup trial (POG 9049/CCG 8882). *J Pediatr Surg* 2001;36:12–17.
655. Marina N, London WB, Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. *J Clin Oncol* 2006;24:2544–2548.
656. Schlatter M, Rescorla F, Giller R, et al. Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children's Cancer Group/Pediatric Oncology Group. *J Pediatr Surg* 2003;38:319–324.
657. Rodriguez-Galindo C, Frailo M, Frazier L, et al. Children's Oncology Group's 2013 blueprint for research: rare tumors. *Pediatr Blood Cancer* 2013;60:1016–1021.
658. Billmire D, Vinocur C, Rescorla F, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. *J Pediatr Surg* 2004;39:424–429.
659. Cushing B, Giller R, Ablin A, et al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group. *Am J Obstet Gynecol* 1999;181:353–358.
660. Mann JR, Gray ES, Thornton C, et al. Mature and immature extracranial teratomas in children: the UK Children's Cancer Study Group Experience. *J Clin Oncol* 2008;26:3590–3597.
661. Dark GG, Bower M, Newlands ES, et al. Surveillance policy for stage I ovarian germ cell tumors. *J Clin Oncol* 1997;15:620–624.
662. Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. *J Clin Oncol* 2000;18:3809–3818.
663. Schwartz CL, Wexler LH, Devidas M, et al. P9754 therapeutic intensification in non-metastatic osteosarcoma: A COG trial. *Ann Meet Am Soc Clin Oncol* 2004;22:Abstract No. 8514.
664. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. *Ann Oncol* 1998;9:893–899.
665. Lewis JJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. *J Natl Cancer Inst* 2007;99;112–128.
666. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. *J Clin Oncol* 2008;26:4385–4393.
667. Sasaki F, Matsunaga T, Iwafuchi M, et al. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Trauma) Protocol-1: a report from Japanese Study Group Pediatric Liver Tumor. *J Pediatr Surg* 2002;37(6):851–856.
668. Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastoma treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: Report from the JPLT. *Pediatr Surg Int* 2011; 27:1–8.